ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.56−0.07 (-0.51%)
Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –
ADMA Biologics net income
Net income is the profit left for shareholders after every expense, interest and tax.
ADMA Biologics's net income for the twelve months ending Jun 30, 2026 was $168.96M, down 19.1% year over year. For fiscal 2025 it was $146.93M, down 25.7% from the year before. The highest annual figure on record is $197.67M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.93M | -25.7% |
| FY2024 | Dec 31, 2024 | $197.67M | – |
| FY2023 | Dec 31, 2023 | -$28.24M | – |
| FY2022 | Dec 31, 2022 | -$65.90M | – |
| FY2021 | Dec 31, 2021 | -$71.65M | – |
| FY2020 | Dec 31, 2020 | -$75.75M | – |
| FY2019 | Dec 31, 2019 | -$48.28M | – |
| FY2018 | Dec 31, 2018 | -$65.74M | – |
| FY2017 | Dec 31, 2017 | -$43.76M | – |
| FY2016 | Dec 31, 2016 | -$19.52M | – |
| FY2015 | Dec 31, 2015 | -$17.97M | – |
| FY2014 | Dec 31, 2014 | -$16.81M | – |
| FY2013 | Dec 31, 2013 | -$15.53M | – |
| FY2012 | Dec 31, 2012 | -$7.30M | – |
| FY2011 | Dec 31, 2011 | -$5.90M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $37.82M | +10.5% |
| Q1 FY2026 | Mar 31, 2026 | $45.33M | +68.5% |
| Q4 FY2025 | Dec 31, 2025 | $49.38M | -55.9% |
| Q3 FY2025 | Sep 30, 2025 | $36.43M | +1.4% |
| Q2 FY2025 | Jun 30, 2025 | $34.22M | +6.7% |
| Q1 FY2025 | Mar 31, 2025 | $26.90M | +51.1% |
| Q4 FY2024 | Dec 31, 2024 | $111.90M | – |
| Q3 FY2024 | Sep 30, 2024 | $35.91M | +1300.0% |
| Q2 FY2024 | Jun 30, 2024 | $32.06M | – |
| Q1 FY2024 | Mar 31, 2024 | $17.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.65M | – |
| Q3 FY2023 | Sep 30, 2023 | $2.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.92M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.18M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.07M | – |
| Q4 FY2018 | Dec 31, 2018 | -$18.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.14M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.98M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.20M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.04M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.54M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.56M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.33M | – |
See a number that looks wrong?